Dernières nouvelles pour V2X (NYSE:VVX) Stock

V2X Inc is a U.S.-based company that provides services to the U.S. government. It operates as one segment and offers facility and logistics services and information technology mission support and engineering and digital integration services. The information technology and network communications capabilities consist of communications systems operations and maintenance, management and service support, systems installation and activation, system-of-systems engineering and software development, and mission support for the department of defense. The facility and logistics service include airfield management, ammunition management, civil engineering, communications, emergency services, life support activities, public works, security, transportation operations, and others.

V2X Inc

BriaCell Therapeutics Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCTX#NASDAQ">BCTX</a>) confirmed on Thursday that it has sustained a complete resolution of the lung metastasis, first reported <a href="https://www.benzinga.com/pressreleases/25/02/g43430846/briacell-announces-resolution-of-lung-metastasis-in-first-patient-treated-with-bria-ots" target="_blank" rel="noopener">in February 2025</a>, two months after the initial treatment in the ongoing Phase 1/2 Bria-OTS study.
The latest data, at four months, also demonstrate <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44975836/briacell-confirms-100-resolution-of-lung-metastasis-with-bria-ots" rel="noreferrer noopener">stable disease elsewhere</a>.
Treatment with Bria-OTS monotherapy resulted in 100% resolution of tumor in the lung of the metastatic breast cancer (MBC) patient following 2 months of therapy. It was confirmed at 4 months of therapy&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">(axial and coronal views)</a>.
The company said the lesion in the patient&#8217;s right lung is undetectable after two months and confirmed resolved at 4 months.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44968420/amentum-offloads-hardware-unit-to-focus-on-critical-services-inks-360-million-deal-with-lockheed-martin" rel="noreferrer noopener">Amentum Offloads Hardware Unit To Focus On Critical Services, Inks $360 Million Deal With Lockheed Martin</a>
The updated images supersede those previously reported.
The patient, a 78-year-old woman with metastatic breast cancer (hormone receptor-positive, HER2 negative), had failed several prior lines of therapy and received the lowest dose level in the Phase 1/2a Bria-OTS study.
At enrollment on November 21, 2024, she had extensive metastases, including bone, lymph node and lung involvement. 
Following Bria-OTS intradermal injections every 2 weeks for six weeks (4 total doses) and subsequent dosing every 3 weeks, the lung metastasis completely resolved with stable disease elsewhere.
Bria-OTS is a personalized off-the-shelf immunotherapy currently under investigation in a Phase 1/2a dose escalation study in metastatic recurrent breast cancer.
The Phase 1/2a trial in metastatic breast cancer is a dose escalation study initially evaluating the safety and efficacy of Bria-OTS as monotherapy. Bria-OTS will follow it in combination with an immune checkpoint inhibitor.
In April, BriaCell Therapeutics released new survival data from its Phase 2 study of Bria-IMT plus checkpoint inhibitors (CPI), which outperformed ADC drugs in hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients.
The survival data of 25 patients (17.3 months) exceeded those of the current ADC standard of care Gilead Sciences Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) Trodelvy <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44835062/briacell-phase-2-survival-data-beats-leading-standard-in-hr-breast-cancer" rel="noreferrer noopener">(sacituzumab govitecan)&nbsp;(14.4 months)</a>.
The survival data for the Bria-IMT regimen + immune checkpoint inhibitor in triple-negative breast cancer (TNBC) was similar to Trodelvy&nbsp;but still markedly higher (70%) than those of chemotherapy.
On Tuesday, BriaCell Therapeutics announced that its ongoing pivotal Phase 3 clinical study for Bria-IMT plus an immune checkpoint inhibitor versus a physician&#8217;s choice in advanced metastatic breast cancer has obtained consent from over 100 patients and has enrolled more than 75.
BriaCell anticipates completing patient enrollment in late 2025 or early 2026 and may report topline data as early as H1-2026.
In February, the company closed a public offering of 762,500 shares at $4.00 per share, raising $3.05 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43509465/briacell-therapeutics-announces-closing-of-public-offering" rel="noreferrer noopener">in gross proceeds</a>.
Price Action: BCTX stock is up 65% at $8.96 during the premarket session at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44968005/whats-going-on-with-chinese-ev-manufacturer-nio-stock-on-wednesday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Chinese EV Manufacturer NIO Stock On Wednesday?</a></li>
</ul>
Photo: Shutterstock

Biotech

News

Health Care

Movers

Trading Ideas

General

BCTX

GILD

Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher

Scotiabank analyst Phil Hardie maintains Guardian Capital Group (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GCG#TSX">GCG</a>) with a Sector Outperform and lowers the price target from C$55 to C$54.

Price Target

Analyst Ratings

TSX:GCG

TSX:GCG/A

Scotiabank Maintains Sector Outperform on Guardian Capital Group, Lowers Price Target to C$54

WIIM

CERO

CERo Therapeutics Holdings shares are trading higher after the company announced the key clinical trial site location for its Phase 1 CER-1236 trial.

<a href="https://www.youtube.com/live/iEpJwprxDdk" title="https://www.youtube.com/live/iEpJwprxDdk">https://www.youtube.com/live/iEpJwprxDdk</a>

Macro Economic Events

Economics

Federal Reserve

Fed's Waller Says It's Possible Tariffs Could Push Up Unemployment Quickly; Struggle Over Last 18 Months Has Been Uneven Inflation Progress; Still Strongly Believes Tariffs Will Be One Time Price Level Effect

JMP Securities analyst Matthew Carletti reiterates Goosehead Insurance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) with a Market Outperform and maintains $150 price target.

Reiteration

GSHD

JMP Securities Reiterates Market Outperform on Goosehead Insurance, Maintains $150 Price Target

Scotiabank analyst Nick Altmann maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Sector Perform and lowers the price target from $19 to $14.

FRSH

Scotiabank Maintains Sector Perform on Freshworks, Lowers Price Target to $14

EGBN

Eagle Bancorp shares are trading lower after the company reported worse-than-expected Q1 financial results.

Fed's Waller Says Not Likely By July There Will Be Clear Tariff Impacts Yet; Easiest Place To Offset Tariff Costs Is By Cutting Payrolls; Send Half Of Year Will Bring Clarity On Tariff Impact; Less Level Of Unemployment But Speed Of Change That's Focus

Century Communities shares are trading lower after the company reported Q1 financial results and missed its adjusted EPS and revenue estimates.

<a href="https://www.youtube.com/live/iEpJwprxDdk">https://www.youtube.com/live/iEpJwprxDdk</a>
&nbsp;

Fed's Waller Says Tariffs Are Part Of Most Economic Debates Now; General Tone Is Many Companies Are Frozen By Tariff Uncertainty; Firms Are Trying To See How To Navigate Tariffs; I Wouldn't Surprise Me To See More Layoffs, Higher Unemployment; Smaller Tariffs Will Have Modest Pass Through; We Need Better Control Of Budget Deficit; No Obvious Reason Why Tariffs Should Be Off Table As Part Of Fiscal Debate

INDV

Indivior shares are trading higher after the company reported better-than-expected Q1 financial results.

Scotiabank analyst Phil Hardie maintains First National Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FN#TSX">FN</a>) with a Sector Perform and lowers the price target from C$45 to C$44.

TSX:FN

Scotiabank Maintains Sector Perform on First National Financial, Lowers Price Target to C$44

APOG

Apogee Enterprises shares are trading lower after the company issued FY26 adjusted EPS and EPS guidance below estimates.

BERWYN, Pa., April 24, 2025 /PRNewswire/ -- Nordic&nbsp;Pharma, Inc., a subsidiary of Nordic Group B.V., announced a partnership with Harrow (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>), a leading North American eyecare company, to launch an authorized generic of Maxitrol&#xAE; (Neomycin and Polymyxin B Sulfates and&nbsp;Dexamethasone Ophthalmic Suspension), which treats and relieves bacterial eye infections.
Maxitrol&#xAE; and generic equivalents had annual sales of $20.8 million in the U.S., according to IQVIA data, as of January 2025.
 &nbsp;

HROW

Nordic Pharma Partners With Harrow To Launch Authorized Generic Of Maxitrol To Treat Bacterial Eye Infections

Scotiabank analyst Phil Hardie maintains Fiera Cap (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FSZ#TSX">FSZ</a>) with a Sector Perform and lowers the price target from C$8.75 to C$7.

TSX:FSZ

Scotiabank Maintains Sector Perform on Fiera Cap, Lowers Price Target to C$7

HELE

Helen of Troy shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results.

JMP Securities analyst Jordan Bender reiterates Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>) with a Market Outperform and maintains $157 price target.

CHDN

JMP Securities Reiterates Market Outperform on Churchill Downs, Maintains $157 Price Target

Scotiabank analyst Phil Hardie maintains Fairfax Financial Hldgs (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FFH#TSX">FFH</a>) with a Sector Outperform and raises the price target from C$2400 to C$2500.

TSX:FFH

Scotiabank Maintains Sector Outperform on Fairfax Financial Hldgs, Raises Price Target to C$2500

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.isolerebio.com%2F&amp;esheet=54243241&amp;newsitemid=20250424252130&amp;lan=en-US&amp;anchor=Isolere+Bio+by+Donaldson&amp;index=1&amp;md5=3db5e8d0847384827cd19b0b45763e74">Isolere Bio by Donaldson</a>, an innovative bioprocessing technology provider, proudly announces the availability of its manufacturing-grade IsoTag&#x2122; AAV reagent for the purification of Adeno-associated Virus (AAV) vectors. As indicated <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.isolerebio.com%2Farticles%2Fresearch-grade-isotag-aav-reagent-announcement&amp;esheet=54243241&amp;newsitemid=20250424252130&amp;lan=en-US&amp;anchor=during+the+launch+of+the+research-grade+reagent&amp;index=2&amp;md5=2fe070e9555e7100349c16f41a752593">during the launch of the research-grade reagent</a> in October 2024, this final advancement in product grade now includes production with validated processes and the availability of a full suite of documentation, including a Regulatory Support File (RSF), validation guide and full design history upon customer request. Additionally, the U.S. Food and Drug Administration (FDA) has acknowledged its receipt of the recently submitted Drug Master File (DMF) for the IsoTag&#x2122; AAV reagent, which will support and streamline clinical manufacturing using the reagent.
 &nbsp;

Isolere Bio By Donaldson Announces Availability Of Manufacturing-grade IsoTag AAV Reagent For Purification Of AAV Vectors

DGICA

Donegal Group shares are trading higher after the company reported better-than-expected Q1 adjusted EPS results.

Earnings

Press Releases

V2X Reports Record Revenue in Fourth Quarter 2024, Driving Strong Year-End Performance

Contracts

V2X to Provide Mission-Critical Aviation Support to the FBI under $100 Million Contract

V2X Wins $100M Contract to Strengthen Missile Defense in Poland and Advance Transatlantic Security

V2X Selected for Navy's WEXMAC 2.0 Contract, Enhancing Global Readiness

V2X Expands Army Training Support with $921 Million BEST MAC Contract

V2X Announces Successful Repricing and Extension of Term Loan and Revolver

V2X to Showcase Readiness Innovations at 2025 Sea-Air-Space Exposition

V2X Delivering Critical Support to U.S. Missile Defense and Space Surveillance Capabilities

Comments

V2X

Actualités

Dernières nouvelles pour V2X (NYSE:VVX) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL